INDIANAPOLIS, Feb. 8 /PRNewswire/ -- Semafore Pharmaceuticals Inc. today announced that Edward L. Jacobs, president and chief executive officer, and Ullrich Schwertschlag, M.D., Ph.D., chief medical officer, will present an update of the company's product development programs at 2:45 p.m. EST on Wednesday, Feb. 13, 2008, at the BIO CEO & Investor Conference in New York City.
The update will include information about Semafore's lead product candidate, SF1126, a targeted PI3 kinase inhibitor currently in Phase 1 clinical trials in solid tumors and multiple myeloma. The presentation will also include a review of the company's pipeline advancements and business development initiatives.
SF1126 is a small molecule conjugate containing a pan-PI3K inhibitor that selectively inhibits all PI3K class IA isoforms and other key members of the PI3K superfamily, including DNA-PK and mTOR. A major factor in tumor resistance to approved chemotherapy agents is thought to be the activation of the PI3K/PTEN pathway. As a result, it is thought that inhibiting this pathway, via SF1126, could cause the resetting of sensitivity to approved agents and exhibit synergistic anticancer effects.
Semafore is a clinical stage drug discovery and development company
focused on small molecule modulators of the PI3 kinase and PTEN cell
signaling pathway, a promising target pathway for multiple disorders,
including the company's focus - cancer. Semafore is one of the first
biopharmaceutical companies to focus on both PI3K and PTEN and has
successfully discovered and is developing a portfolio of drug candidates
addressing these targets. For more information see the company's Web site
Semafore Pharmaceuticals Inc. Russo Partners LLC
|SOURCE Semafore Pharmaceuticals Inc.|
Copyright©2008 PR Newswire.
All rights reserved